Over the past year, Novartis has struck a pair of deals in Israel, snagging an option to buy Gamida Cell and a stake in BioLineRx.
Shire CEO Flemming Ornskov has come out fighting against vocal critics of the company's tax model. As Ornskov sees it, Shire's tax structure is fully legal, similar to the model used by around 500 companies and beneficial to patients.
Last November the upstart biotech Pronutria Biosciences landed Peter Mueller as its R&D chief shortly after he stepped aside from his starring role as research chief for Vertex. And now Pronutria has landed $28 million in financing to advance its drug development efforts.
A new study from American and Israeli researchers has shown that nanostructures used to deliver cancer drugs act differently within the local area of a tumor than they do in healthy cells, a finding that could change the way these nanomaterials are made and how they target their drug release.
Sanofi has inked a discovery-stage agreement in hopes of developing a fleet of new autoimmune disease treatments, homing in on a novel pathway alongside a Dutch biotech.
Rare disease specialist Genzyme talked up the results of a study published in The Journal of the American Medical Association concluding that the only first-line oral therapy for Gaucher disease reduced spleen size 28% compared to placebo after 9 months.
Looking to tie its two big R&D hubs in Cambridge, U.K., and Gothenburg, Sweden, closer together, AstraZeneca has struck a deal to reserve 20 seats on a Sun Air flight that will make a round-trip journey each day from Monday through Thursday.
The real-time use of MRIs and CT scans during surgery is becoming increasingly prevalent and improving patient outcomes. The images produced by intraoperative imaging techniques allow surgeons to make more precise cuts, thereby sparing healthy tissue and bone, and reducing the need for repeat procedures.
CRO giant inVentiv Health is opening an early-stage clinic in Miami, expanding its global Phase I services to the U.S. with an emphasis on complex studies.
Developers have come up with a telescopic contact lens that can alternate between normal and magnified vision with the blink of an eye, and has the potential to help people suffering from macular degeneration.